Highlights
- Market Cap
- $257.67M
- Enterprise Value
- $270.67M
- EPS (TTM)
- -$0.90
- Total Revenue (TTM)
- $36.97M
- Gross Profit (TTM)
- $22.69M
- EBITDA (TTM)
- -$24.16M
- Year Range
- $8.60 - $30.10
- Target Price
- $18.00
- ROA (TTM)
- -26.13%
- ROE (TTM)
- -91.15%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ClearPoint Neuro, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
ClearPoint Neuro, Inc. (CLPT) has returned -33.48% so far this year and -23.47% over the past 12 months.
ClearPoint Neuro, Inc.
- 1D
- 5.08%
- 1M
- -27.61%
- YTD
- -33.48%
- 6M
- -58.24%
- 1Y
- -23.47%
- 3Y*
- 2.54%
- 5Y*
- -15.86%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Feb 12, 2020, CLPT's average daily return is +0.15%, while the average monthly return is +2.97%. At this rate, your investment would double in approximately 2.0 years.
Historically, 43% of months were positive and 57% were negative. The best month was Sep 2025 with a return of +107.7%, while the worst month was Nov 2025 at -37.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CLPT closed higher 47% of trading days. The best single day was Sep 24, 2025 with a return of +58.6%, while the worst single day was Mar 2, 2026 at -22.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.48% | -2.78% | -27.61% | -33.48% | |||||||||
| 2025 | 13.52% | -16.84% | -18.11% | 21.03% | -17.93% | 1.10% | -12.90% | 0.87% | 107.72% | 6.56% | -37.73% | -5.39% | -11.05% |
| 2024 | 2.50% | -8.19% | 6.42% | -20.15% | 0.00% | -0.74% | 32.84% | 81.28% | -13.64% | 10.53% | -0.16% | 24.33% | 126.51% |
| 2023 | 12.28% | -10.83% | -0.47% | 24.64% | -26.81% | -5.97% | -5.11% | -15.43% | -13.77% | 9.78% | 4.73% | 17.88% | -19.83% |
| 2022 | -21.30% | -0.91% | 18.97% | -17.68% | 27.89% | 19.07% | 8.58% | -9.17% | -19.50% | -3.38% | -5.79% | -10.18% | -24.51% |
| 2021 | 48.71% | -0.89% | -9.74% | -1.47% | -11.57% | 3.64% | 16.45% | -15.11% | -5.94% | -5.75% | -17.93% | -18.28% | -29.39% |
Benchmark Metrics
ClearPoint Neuro, Inc. has an annualized alpha of 23.81%, beta of 1.34, and R² of 0.12 versus S&P 500 Index. Calculated based on daily prices since February 13, 2020.
- This stock participated in 110.15% of S&P 500 Index downside but only 99.59% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.12 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 23.81%
- Beta
- 1.34
- R²
- 0.12
- Upside Capture
- 99.59%
- Downside Capture
- 110.15%
Return for Risk
Risk / Return Rank
CLPT ranks 33 for risk / return — below 33% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ClearPoint Neuro, Inc. (CLPT) and compare them to a chosen benchmark (S&P 500 Index).
| CLPT | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.23 | 0.90 | -1.13 |
Sortino ratioReturn per unit of downside risk | 0.34 | 1.39 | -1.05 |
Omega ratioGain probability vs. loss probability | 1.04 | 1.21 | -0.17 |
Calmar ratioReturn relative to maximum drawdown | -0.34 | 1.40 | -1.74 |
Martin ratioReturn relative to average drawdown | -0.63 | 6.61 | -7.24 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore CLPT risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the ClearPoint Neuro, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ClearPoint Neuro, Inc. was 84.62%, occurring on Nov 10, 2023. Recovery took 477 trading sessions.
The current ClearPoint Neuro, Inc. drawdown is 69.26%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -84.62% | Feb 17, 2021 | 690 | Nov 10, 2023 | 477 | Oct 8, 2025 | 1167 |
| -70.74% | Oct 9, 2025 | 118 | Mar 30, 2026 | — | — | — |
| -49.51% | Feb 14, 2020 | 64 | May 15, 2020 | 105 | Oct 14, 2020 | 169 |
| -19.51% | Oct 19, 2020 | 13 | Nov 4, 2020 | 7 | Nov 13, 2020 | 20 |
| -10.75% | Dec 1, 2020 | 11 | Dec 15, 2020 | 2 | Dec 17, 2020 | 13 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ClearPoint Neuro, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ClearPoint Neuro, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CLPT relative to other companies in the Medical Devices industry. Currently, CLPT has a P/S ratio of 7.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CLPT in comparison with other companies in the Medical Devices industry. Currently, CLPT has a P/B value of 9.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |